Spots Global Cancer Trial Database for Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma
Official Title: ML42362: Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma
Study ID: NCT04710498
Conditions
Interventions
Study Description
Brief Summary: The purpose of this research is to evaluate whether the administration of atezolizumab before surgical resection of your tumor is feasible and to evaluate the treatment response, safety, and tolerability of atezolizumab.
Detailed Description: Primary Objective: Determine the feasibility of three doses of atezolizumab prior to surgery in patients with advanced cutaneous squamous cell carcinoma Secondary Objectives: * Assess response rates to neoadjuvant atezolizumab Objective response rate following completion of neoadjuvant therapy based on RECIST 1.1 criteria oPathological response rate (major and complete pathological response) in final surgical resection specimen * Assess change in surgical margins or vital structures preserved following neoadjuvant treatment * Assess safety and tolerability of neoadjuvant atezolizumab
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Stanford University, Stanford, California, United States
Contact Details
Name: Vasu Divi, MD
Affiliation: Stanford Universiy
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
